EGFR ligand switch in late stage prostate cancer contributes to changes in cell signaling and bone remodeling
- 13 January 2009
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 69 (5) , 528-537
Abstract
BACKGROUND: Bone metastasis occurs frequently in advanced prostate cancer (PCa) patients; however, it is not known why this happens. The epidermal growth factor receptor (EGFR) ligand EGF is available to early stage PCa; whereas, TGF‐α is available when PCa metastasizes. Since the microenvironment of metastases has been shown to play a role in the survival of the tumor, we examined whether the ligands had effects on cell survival and proliferation in early and late PCa.METHODS: We used LNCaP cells as a model of early stage, non‐metastatic PCa and the isogenic C4‐2B cells as a model of late stage, metastatic PCa.RESULTS: We found that the proliferation factor MAPK and the survival factor AKT were differentially activated in the presence of different ligands. TGF‐α induced growth of C4‐2B cells and not of the parental LNCaP cells; however, LNCaP cells expressing a constitutively active AKT did proliferate with TGF‐α. Therefore, AKT appeared to be the TGF‐α‐responsive factor for survival of the late stage PCa cells. LNCaP cells exposed to EGF produced more osteoprotegerin (OPG), an inhibitor of bone remodeling, than C4‐2B cells with TGF‐α, which had increased expression of RANKL, an activator of bone remodeling. In concordance, TGF‐α‐treated C4‐2B conditioned medium was able to differentiate an osteoclast precursor line to a greater extent than EGF‐treated C4‐2B or TGF‐α‐treated LNCaP conditioned media.CONCLUSION: The switch in EGFR ligand availability as PCa progresses affects cell survival and contributes to bone remodeling. Prostate 69:528–537, 2009.Keywords
This publication has 44 references indexed in Scilit:
- Evidence for Disease Control with Erlotinib after Gefitinib Failure in Typical Gefitinib-Sensitive Asian Patients with Non-small Cell Lung CancerJournal of Thoracic Oncology, 2008
- Potentiation of antitumour activity of docetaxel by combination with trastuzumab in a human prostate cancer xenograft model and underlying mechanismsBritish Journal of Cancer, 2007
- The role of Wnts in bone metastasesCancer and Metastasis Reviews, 2006
- Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude miceEndocrine-Related Cancer, 2006
- Gefitinib–trastuzumab combination on hormone-refractory prostate cancer xenograftEuropean Journal of Cancer, 2005
- Osteoblasts in prostate cancer metastasis to boneNature Reviews Cancer, 2005
- Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activityThrombosis and Haemostasis, 2005
- erbB-2 Overexpression in Human Mammary Epithelial Cells Confers Growth Factor IndependenceEndocrinology, 1999
- Identification and interpretation of epidermal growth factor and c-erbB-2 overexpressionEuropean Journal of Cancer, 1992
- RECEPTORS FOR EPIDERMAL GROWTH FACTOR AND OTHER POLYPEPTIDE MITOGENSAnnual Review of Biochemistry, 1987